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Abstract: There is evidence that patients with the metabolic syndrome have altered platelet indices 
including higher mean platelet volume. According to the 2009 International Diabetes Federation cri-
teria of metabolic syndrome diagnosis, elevated waist circumference (≥94 cm in M, ≥80 cm in F), as 
a determinant of abdominal obesity, is not an obligatory component. 
P u r p o s e: The aim of this study was to evaluate the relationship between platelet indices, including 
mean platelet volume, and abdominal obesity in patients with metabolic syndrome. 
M e t h o d s: 382 consecutive patients were enrolled in the study and divided into three groups: group A, 
218 patients with metabolic syndrome and abdominal obesity (132 M, mean age 65.3 ± 10.9 yrs); group B, 
35 patients with metabolic syndrome without abdominal obesity (28 M, mean age 63.3 ± 11.2 yrs); 
and, group C, 129 patients without metabolic syndrome and without abdominal obesity (99 M, mean 
age 62.2 ± 13.8 yrs).
R e s u l t s: In group A, mean platelet volume was significantly higher than in group C (10.70 ± 1.01 vs. 
10.35 ± 0.94 fL, p = 0.007). However, there was no difference in mean platelet volume between group A 
and B (10.70 ± 1,01vs. 10.63 ± 1.03 fL, p >0.05). Furthermore, in group A, mean platelet volume was 
correlated with waist circumference (r = 0.14, p = 0.041) and body mass index (r = 0.14, p = 0.045). 
In all study groups, a significant association between mean platelet volume and platelet count (r = –0.33, 
p <0.001) was found.
C o n c l u s i o n: In individuals with metabolic syndrome and abdominal obesity mean platelet volume 
is positively correlated with waist circumference and significantly higher than in patients without these 
abnormalities.
Key words: platelets activity, mean platelet volume, abdominal obesity, metabolic syndrome, cardio-
vascular risk.
INTRODUCTION
The risk for developing cardiovascular disease is linked to a group of common 
disorders (including obesity, diabetes, dyslipidemia and hypertension) which are 
collectively termed the metabolic syndrome [1]. Abdominal obesity is one of a most 
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prevalent risk factor of cardiovascular disease. According to the current defini-
tion, the metabolic syndrome may be diagnosed in individuals who do not meet 
the criterion of elevated waist circumference, as a marker of abdominal obesity 
(e.g. for the European population waist circumference of ≥94 cm in M, ≥80 cm 
in F) [2]. Abdominal obesity together with the metabolic syndrome can favour the 
development of atherosclerosis, which is the main cause of coronary disease [3]. 
However, patients without abdominal obesity, but who meet other criteria of the 
metabolic syndrome, are still prone to development of cardiovascular disease. 
Such patients are often described as ‘metabolically obese normal weight individ-
uals’ (MONW) [4].
The search for simple markers that allow for early identification of the pa-
tients being at highest risk from cardiovascular events is ongoing. Considering 
the increasing social problem of the metabolic syndrome and abdominal disease, 
proper recognition of the risk and early prevention of cardiovascular disease is 
crucial.
In the pathophysiology of ischaemic heart disease, the process of platelet ac-
tivation plays an essential role [5]. Mean platelet volume (MPV) is an acces-
sible marker of platelet activity [6, 7]. Platelets with a high volume produce 
a considerable amount of the vasoactive and haemostatic substances, such as 
thromboxane A2, serotonin or adenosine triphosphate (ATP), causing them to 
aggregate more quickly. Moreover, there are numerous adhesion molecules on 
the platelet surface, which participate in thrombus formation [8, 9]. Thus, in-
creased MPV value is connected to the hyperaggregability and shortened time of 
coagulation [10]. 
Recent studies have assigned the process of platelet activation as vital for the 
development of cardiovascular disease [11]. The increased MPV is associated with 
increased risk of cardiac arrest, including death as its aftermath, and an elevat-
ed risk of a restenosis after coronary angioplasty [11]. Similarly, in patients with 
cerebral stroke, an increased MPV has been observed signaling increased platelet 
activity [12]. It has also been shown that patients with the metabolic syndrome 
have an increased MPV value and thus, have an increased risk of cardiovascu-
lar disease [13]. However, the importance of the MPV value has not been fully 
investigated in patients with the metabolic syndrome that do not meet the ab-
dominal obesity criteria. 
The aim of the study was to assess the correlation between the platelet mark-
ers, especially the MPV, and the incidence of abdominal obesity in patients with 
the metabolic syndrome. Similarly, whether MPV is determined by the degree of 
abdominal obesity was investigated. Moreover, we highlight the potential of MPV 
as a simple marker to allow for early identification of patients with an increased 
risk of cardiovascular disease. 
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MATERIALS AND METHODS
The retrospective analysis included 382 patients hospitalized in 2009–2010 in the 
Department of Coronary Disease of the Jagiellonian University Medical College 
[Klinika Choroby Wieńcowej Instytutu Kardiologii Uniwersytetu Jagiellońskiego 
Collegium Medicum]. The inclusion criteria were: diagnosis of metabolic syndrome 
according to the International Diabetes Federation definition from 2009 (Table 1), 
age 18–90 years old and taking acetylosalicic acid 75 mg per day. The exclusion 
criteria for the study were: decompensation of heart failure, thromboembolic dis-
ease and acute inflammation upon admission, taking any antiplatelet agent other 
than acetylosalicic acid, diagnosed cancer. 
T a b l e  1
Diagnosis of metabolic syndrome in patients included into the study was based  
on a co-occurrence of three out of five of the following criteria [2].
Elevated waist circumference, for the European population ≥94 cm in M and ≥80 cm in F
Elevated triglycerides ≥1.7 mmol/L (150 mg/dL) or drug treatment for elevated triglycerides 
(fibrates)
Reduced  HDL-C <1.0 mmol/L (40 mg/dL) in M and <1.3 mmol/L (50 mg/dL) in F or drug 
treatment for reduced HDL-C (fibrates)
Elevated blood pressure: systolic ≥130 mmHg and/or diastolic ≥85 mmHg or antihypertensive 
drug treatment in a patient with a history of hypertension 
Elevated fasting glucose ≥5.6 mmol/L (100 mg/dL) or drug treatment of elevated glucose
Abbreviations: HDL-C — high density lipoprotein cholesterol, M — male, F — female
The anthropometric measurements were conducted in all patients upon ad-
mission to the hospital including height, body mass and waist circumference. On 
the basis of metabolic syndrome and abdominal obesity diagnosis patients were 
divided into three study groups: group A, 218 patients with metabolic syndrome 
and abdominal obesity; group B, 35 patients with metabolic syndrome without 
abdominal obesity; and group C (control group), 129 patients without metabol-
ic syndrome and without abdominal obesity. Selected platelet indices such as 
MPV and platelet blood count were measured for each patient by means of an 
automatic hematology analyzer SYSMEX XS-1000i in the Analytical Laborato-
ry in the John Paul II Hospital in Krakow. Platelet blood count and MPV val-
ue were determined with use of impedance method and hydrodynamic focusing 
method. 
The STATISTICA 10 software package was used to compare the platelet mark-
er values (such as MPV and the platelet count), the demographic data, the in-
cidence of ischemic heart disease and chronic heart failure between the three 
groups. To compare quantitative variables, the analysis of variance (ANOVA) or 
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its nonparametric counterpart (the Kruskal–Wallis one-way analysis of variance 
by ranks) were used. For qualitative variables, the chi square test (X2) was used. 
The post-hoc tests included the Scheffe’s method and the least significant differ-
ence test (LSD). In order to assess the correlation between MPV value and other 
examined variables, the Pearson correlation coefficient and the Spearman cor-
relation coefficient were implemented. 
RESULTS
The basic characteristics and drug treatment in the examined groups are pre-
sented in Table 2 and Table 3. The examined groups did not differ significantly 
T a b l e  2
Basic characteristics of the study groups.
Parameter
Group A
n = 218
Group B
n = 35
Group C
n = 129
P value  
(between 
marked 
groups)
Male, n (%) 132 (60.6) 28 (80) 99 (76.7) 0.035a
Age, [years] 65.3 ± 10.9 63.3 ± 11.2 62.2 ±13.8 NS
Body mass, [kg] 84.2 ± 14.1 70.3 ± 10.1 65.1 ±9.8 <0.0001a,c
BMI, [kg/m2] 29.4 ± 4.1 24.3 ± 2.1 23 ± 2.7 <0.0001a,c
Waist circumference, [cm] 102.9 ± 13.3 85.3 ± 7.6 82.9 ± 7.4 <0.0001a,c
Abdominal obesity, n (%) 218 (100) 0 0 <0.0001a,c
Hypertension, n (%) 205 (94) 34 (97.1) 19 (14.7) <0.0001a,b
Diabetes mellitus type 2, n (%) 88 (40.4) 15 (42.9) 4 (3.1) <0.0001a,b
IGT, n (%) 31 (14.2) 4 (11.4) 4 (3.1) NS 
IFG, n (%) 31 (14.2) 5 (14.3) 1 (0.8) NS 
Hypercholesterolemia, n (%) 116 (53.2) 21 (60) 81 (62.8) NS 
Hypertriglyceridemia, n (%) 18 (8.3) 1 (2.9) 3 (2.3) NS 
Mixed hyperlipidemia, n (%) 64 (29.4) 13 (37.1) 16 (12.4) 0.03a
Ischemic heart disease, n (%) 199 (91.3) 33 (94.3) 102 (79.1) NS
Chronic heart failure, n (%) 54 (24.8) 9 (25.7) 28 (21.7) NS
Diastolic dysfunction, n (%) 96 (44) 14 (40) 63 (48.8) NS
LVEF, [%] 51.7 ± 11.7 53.4 ± 11.1 51.8 ± 13.8 NS
a gr. A vs. gr. C; b gr. B vs. gr. C; c gr. A vs. gr. B;
Data are expressed as mean ± standard deviation or number of patients (percentage).
Abbreviations: BMI — body mass index; IFG — impaired fasting glucose; IGT — impaired glucose tolerance; LVEF 
— left ventricle ejection fraction.
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T a b l e  3
Drug treatment in study groups.
Drug
Group A
n = 218
Group B
n = 35
Group C
n = 129
P value (between 
marked groups)
ASA, n (%) 218 (100) 35 (100) 129 (100) NS
Clopidogrel, n (%) 0 0 0 NS
Antidiabetic drugs, n (%) 68 (31.2) 10 (28.6) 3 (2.3) <0.0001a
Insulin, n (%) 30 (13.8) 4 (11.4) 2 (1.6) NS
Statin, n (%) 202 (92.7) 33 (94.3) 101 (78.3) NS
Fibrate, n (%) 9 (4.1) 1 (2.9) 4 (3.1) NS
ACEI/ARB, n (%) 205 (94) 34 (97.1) 88 (68.2)
0.0002a
0.0259b
Beta blocker, n (%) 189 (86.7) 32 (91.4) 81 (62.8)
0.0006a
0.0280b
Diuretic, n (%) 108 (49.5) 14 (40) 42 (32.6) 0.025a
Calcium channel blocker, n (%) 65 (29.8) 8 (22.9) 31 (24) NS
Alpha blocker, n (%) 18 (8.3) 1 (2.9) 7 (5.4) NS
a gr. A vs. gr. C; b gr. B vs. gr. C; c gr. A vs. gr. B;
Data are expressed as number of patients (percentage).
Abbreviations: ACEI — angiotensin-converting enzyme inhibitor; ARB — angiotensin receptor blocker; ASA — ace-
tylsalicylic acid.
according to the incidence of ischemic heart disease. Similarly, the increase of 
the angina pectoris symptoms in all groups was comparable — the median angi-
na grade was II according to Canadian Cardiovascular Society (CCS) scale. Fur-
thermore, there were no differences in the incidence of chronic heart failure, left 
ventricular ejection fraction value, or the incidence of the left ventricular diastolic 
dysfunction, assessed on the basis of transthoracic echocardiograms.
Considering the platelet parameters, the platelet blood count did not differ sig-
nificantly between the examined groups. However, there were some differences in 
the MPV values. The highest MPV value was observed in the metabolic syndrome 
and abdominal obesity group (group A) and this value was statistically signifi-
cant from the patients with no metabolic syndrome (group C). This analysis has 
not revealed any considerable differences in the MPV value between groups with 
metabolic syndrome (groups A and B) (Table 4).
Moreover, only in patients with metabolic syndrome and abdominal obesity 
(group A), a weak but statistically significant correlation between the MPV value 
and waist circumference and the body mass index (BMI) was observed (r = 0.14, 
p = 0.041, and r = 0.14, p = 0.045, respectively) (Fig. 1, 2). In all examined 
groups, a negative correlation between the MPV value and platelet blood count 
was shown (r = –0.33, p <0.001) (Fig. 3).
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T a b l e  4
Laboratory parameters between study groups.
Parameter
Group A 
n = 218
Group B 
n = 35
Group C 
n = 129
P  value  
(between marked groups)
PLT, [×109/L] 225.8 ± 79.1 224.5 ± 57.1 226.0 ± 69.7 NS
MPV, [fL] 10.70 ± 1.01 10.63 ± 1.03 10.35 ± 0.94 0.007a
TC, [mmol/L] 4.68 ± 1.35 4.59 ± 1.16 4.89 ± 1.29 NS
TG, [mmol/L] 1.47 ± 0.89 1.39 ± 0.83 1.09 ± 0.72 0.0004a
LDL-C, [mmol/L] 2.68 ± 1.02 2.62 ± 0.97 2.86 ± 1.03 NS
HDL-C, [mmol/L] 1.17 ± 0.32 1.23 ± 0.31 1.29 ± 0.31 0.003a
a gr. A vs. gr. C; b gr. B vs. gr. C; c gr. A vs. gr. B;
Data are expressed as mean ± standard deviation.
Abbreviations: PLT — platelet count; MPV — mean platelet volume; HDL-C — high-density lipoprotein cholesterol; 
LDL-C — low-density lipoprotein cholesterol; TC —  total cholesterol, TG — triglycerides
Fig. 1. Correlation between mean platelet volume (MPV) and waist circumference in patients 
with metabolic syndrome and abdominal obesity (group A).
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Fig. 2. Correlation between mean platelet volume (MPV) and body mass index (BMI) in patients 
with metabolic syndrome and abdominal obesity (group A).
Fig. 3. Correlation between platelet count (PLT) and mean platelet volume (MPV) in study population.
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DISCUSSION
Patients with the metabolic syndrome are characterized by increased platelet ac-
tivity and thus, are more prone to cardiovascular disease. To date, the occurrence 
of abdominal obesity in patients with metabolic syndrome has not been prov-
en to affect the platelet size considerably. However, in patients with abdominal 
obesity, there is a correlation between their waist circumference and the volume 
and activity of their platelets. Indeed, current studies have revealed that in obese 
individuals, the MPV value is larger compared to those of healthy weight [14]. 
Moreover, body mass reduction in these obese individuals is correlated with 
a decrease in their MPV value [15, 16].
The precise correlation mechanism between abdominal obesity and the activ-
ity of platelets has not been thoroughly explained. It is certain that in the obese 
patients there is a considerable amount of a metabolically active adipose tissue 
covering the organs in the abdominal cavity. This adipose tissue constitutes an 
endocrine organ secreting numerous active substances [17]. For example, the ad-
ipose tissue secretes a considerable amount of the plasminogen activator inhibi-
tor-1 (PAI-1), which is responsible for inhibition of fibrinolysis, the physiological 
process of atherothrombus decomposition [18]. 
The adipose tissue also has an increased sensitivity to adrenergic stimula-
tion, which increases the release of free fatty acids into the portal venous sys-
tem. These free fatty acids will, in turn, influence liver metabolism, favouring the 
release of glucose and production of very-low-density lipoproteins (VLDL) [19]. 
As a result, development of lipid disorders, glucose metabolism disorders and 
hyperinsulinemia begin [20]. Insulin is a hormone that stimulates the creation 
of bigger platelets in a process termed megakaryocytopoiesis [20]. The presence 
of these high volume platelets in patients indicates an increased consumption 
of smaller volume platelets [21]. The increased platelet rotation results in a re-
verse correlation between the total number of platelets and MPV as the organism 
maintains a constant level of total platelet mass [22]. Furthermore, the increased 
consumption of small platelets constitutes a strong stimulus for the creation of 
bigger platelets from megakaryocytes in bone marrow [23].
Although no correlation between MPV value and accompanying occurrence of 
abdominal obesity has been found in patients with the metabolic syndrome, the 
probability of its existence cannot be excluded. One should bear in mind that 
in the study described above the group of patients with the metabolic syndrome 
and without abdominal obesity was rather small (35 patients). Currently, the cri-
teria for abdominal obesity diagnosis are more strict than before. It is also worth 
highlighting that the occurrence of risk factors such as diabetes, hypertension or 
lipid disorders are considerably more frequent in patients with abdominal obesity, 
which often initiates the metabolic syndrome development. Hence, there are few 
individuals with metabolic syndrome of normal body weight. Current research 
63
shows that in the Polish population fewer than 1% of people [24] with normal 
body weight meet the criteria of the metabolic syndrome, while in the European 
population the percentage is 7% [25]. Considering the complexity of metabolic 
disorders present in patients with the metabolic syndrome, further investigation 
of factors influencing cardiovascular risk in this group is recommended.
To conclude, MPV is a simple, low-cost and accessible marker of platelet ac-
tivity that could be used in everyday clinical practice to assess cardiovascular 
risk. The marker is especially useful in patients with the metabolic syndrome and 
abdominal obesity for its value correlates positively with waist circumference. The 
combination of these two intertwined indices could possibly enable easy identifi-
cation of patients with a high risk of cardiovascular disease for early implemen-
tation of effective prevention methods. It is worth promoting the application of 
these simple indices in clinical practice. As body mass reduction may ultimately 
lead to a reduction in platelet volume, it may be profitable to use MPV not only 
as a risk marker but also as a therapeutic goal.
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